Evidence map›Paper›PMID 29038432›Full record

Trial reportScientific reports2017

Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study.

Yong Zhang, Chun Han, Juan Li, Li Zhang, Lijie Wang, Sisi Ye, Yi Hu, Li Bai

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. A Rare Case of Small Bowel Ulceration Induced by COVID-19.Journal of inflammation research · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Tumor vessel normalization and immunotherapy in gastric cancer.Therapeutic advances in medical oncology · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yong ZhangOncology Department, Chinese PLA General Hospital, Beijing, China.
Chun HanOncology Department, Chinese PLA General Hospital, Beijing, China.
Juan LiOncology Department, Chinese PLA General Hospital, Beijing, China.
Li ZhangOncology Department, Chinese PLA General Hospital, Beijing, China.
Lijie WangOncology Department, Chinese PLA General Hospital, Beijing, China.
Sisi YeOncology Department, Chinese PLA General Hospital, Beijing, China.
Yi HuOncology Department, Chinese PLA General Hospital, Beijing, China.
Li BaiOncology Department, Chinese PLA General Hospital, Beijing, China. baili_0795@hotmail.com.
Chinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apatinib has been proved to be effective and safe among patients in gastric cancer in Phase II and III Trials. We aimed to evaluate its efficacy and safety in real world practice, and to explore factors associated with efficacy. Between January 2015 and February 2017, totally 36 patients with advanced gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction (GEJ) were enrolled and followed up retrospectively after failing at least two lines of systemic therapy. The mPFS was 2.65 months (95%CI 1.66-3.54), and mOS was 5.8 months (95%CI 4.77-6.83). Two patients achieved partial response, and nineteen achieved stable disease. The disease control rate (DCR) was 58.3%, and objective response rate (ORR) was 5.6%. Common grade adverse events were hypertension (38.9%), proteinuria (36.1%), and neutropenia (33.3%). And the most common adverse events over grade 3 were hand-foot syndrome (8.3%), anemia (5.6%), and diarrhea (5.6%). No treatment-related death was documented during the drug administration. Exploratory analyses indicated patients treated with antiangiogenic therapy previously were more likely to benefit from apatinib.

Indexed as

AdenocarcinomaAdultAgedAntineoplastic AgentsDisease-Free SurvivalEsophagogastric JunctionFemaleHumansMaleMiddle AgedPyridinesStomach NeoplasmsAntineoplastic AgentsapatinibPyridines

Identifiers

PMID29038432
PMCPMC5643341
OpenAlexW2762884277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.